Quest Diagnostics Inc Proceeds from (Repayments of) Bank Overdrafts
Quest Diagnostics Inc (DGX) reported Proceeds from (Repayments of) Bank Overdrafts of -$110.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfBankOverdrafts · last filed 2026-07-23
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for the quarter ending 2009-12-31 was $4.29M, a 66.42% decline year-over-year.
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for the quarter ending 2009-09-30 was $3.36M, a 39.91% decline year-over-year.
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for the quarter ending 2008-12-31 was $12.78M.
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for the quarter ending 2008-09-30 was $5.59M.
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for fiscal 2025 was $41.00M, a 24.24% increase from fiscal 2024.
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for fiscal 2024 was $33.00M, a 8.33% decline from fiscal 2023.
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for fiscal 2023 was $36.00M.
- Quest Diagnostics Inc proceeds from (repayments of) bank overdrafts for fiscal 2022 was -$24.00M.
| Period end | Proceeds from (Repayments of) Bank Overdrafts 3 month | Proceeds from (Repayments of) Bank Overdrafts 6 month | Proceeds from (Repayments of) Bank Overdrafts 9 month | Proceeds from (Repayments of) Bank Overdrafts 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$110.00M 10-Q · filed 2026-07-23 | |||
| 2025-12-31 | $41.00M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | -$50.00M 10-Q · filed 2026-07-23 | |||
| 2024-12-31 | $33.00M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $36.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$24.00M 10-K · filed 2025-02-20 | |||
| 2009-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2010-02-17 | $7.65M derived: sum of 2 quarters · filed 2010-02-17 | -$12.09M 10-K · filed 2010-02-17 | |
| 2009-09-30 | $3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-27 | -$16.39M 10-Q · filed 2009-10-27 | ||
| 2009-06-30 | -$19.74M 10-Q · filed 2009-07-28 | |||
| 2008-12-31 | $12.78M derived: 10-K 12 month − 10-Q 9 month · filed 2010-02-17 | $18.37M derived: sum of 2 quarters · filed 2010-02-17 | $14.20M 10-K · filed 2010-02-17 | |
| 2008-09-30 | $5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-27 | $1.42M 10-Q · filed 2009-10-27 | ||
| 2008-06-30 | -$4.17M 10-Q · filed 2009-07-28 | |||
| 2007-12-31 | -$24.95M 10-K · filed 2010-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |